Re: First-in-Human Safety, Imaging, and Dosimetry of a Carbonic Anhydrase IX-Targeting Peptide, [68Ga]Ga-DPI-4452, in Patients with Clear Cell Renal Cell Carcinoma
-
Published:2024-09
Issue:3
Volume:86
Page:284-285
-
ISSN:0302-2838
-
Container-title:European Urology
-
language:en
-
Short-container-title:European Urology
Author:
Thomson Alice,
Castillo Carlotta,
Graefen Henrike,
Perera Sachin,
Lawrentschuk Nathan,
Perera Marlon,
Eapen Renu,
Murphy Declan G.ORCID
Reference8 articles.
1. Hofman MS, Tran B, Feldman DR, et al. First-in-human safety, imaging, and dosimetry of a carbonic anhydrase IX-targeting peptide, [68Ga]Ga-DPI-4452, in patients with clear cell renal cell carcinoma. J Nucl Med. In press. https://doi.org/10.2967/jnumed.123.267175.
2. Impact of prostate-specific membrane antigen positron emission tomography/computed tomography in the management of oligometastatic renal cell carcinoma;Udovicich;Eur Urol Open Sci,2022
3. Targeted PET/CT imaging for clear cell renal cell carcinoma with radiolabeled antibodies: recent developments using girentuximab;Van Oostenbrugge;Curr Opin Urol,2021
4. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study;Hofman;Lancet,2020
5. The additive diagnostic value of prostate-specific membrane antigen positron emission tomography computed tomography to multiparametric magnetic resonance imaging triage in the diagnosis of prostate cancer (PRIMARY): a prospective multicentre study;Emmett;Eur Urol,2021